ABC - Earnings call transcript Q3 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the AmerisourceBergen Third Quarter Earnings Conference Call. At this time all participants are in a listen only mode, later we will conduct a question and answer session. [Operator Instructions].

I would like to now turn the conference over to our host, Mr. Bennett Murphy. ahead. go Please

Bennett Murphy

Investor morning Jim for Good XXXX you for CFO. President Vice all quarter are me Thank Collis, Executive Steve conference and Vice call us Chairman, President, Murphy, Bennett this results. CEO; fiscal and to joining joining financial today and you. and I'm thank Relations, Cleary, discuss third and AmerisourceBergen's President

release of and be slide these we press also also today's will discussing in website. non-GAAP investor today's measures, We've provided call, on release our press to measures presentation on reconciliations are GAAP available today's investor.amerisourcebergen.com. website are On financial our to at accompany a posted

During and business not including this statements but forward-looking expectations income we to, non-GAAP about make EPS, operating basis, taxes. and limited conference income our on call, will financial an adjusted

on uncertainty to Forward-looking current statements and are change. based are expectations and subject management's

most release the no statements today's call For of SEC filings, a you refer be and discussion to our XX-K. Company. of the we permission key and without any rebroadcast forward-looking our assumptions, cannot to update and recent AmerisourceBergen press expressed this risks including obligation assumes

per you questions your have ask within possible opportunity we remarks questions us that get order in You by many an to management, today's after participants as for ask to one to participant as limit to the hour.

Steve? I that, Steve. call turn will to With over the

Steve Collis

position continue good long-term AmerisourceBergen's and everyone advancing we play and Today, The third growth. on healthcare the we to systems Bennett, XXXX. morning performance for to continued of culture people, strong and in discuss you, in pleased role Thank strategy critical today's fiscal to our AmerisourceBergen quarter call. I'm how US the

increase billion and performance. XXXX to of third period. XX% a the the fiscal to an EPS year quarter our quarter, First, for increased previous was X% Revenues $X.XX, diluted our compared fiscal financial solid adjusted $XX.X

the Commercialization continued & performance groups. pleased overall and Global by extremely Services Pharmaceutical Animal the We Distribution Health strong are with both

product specialty of sales, and strong strength continued largest customers execution, overall solid reflect the our some growth businesses. results quarter's This of our across

segment business operating quite our Services manufacturer work Distribution and distribution and income Pharmaceutical diligently as our efficiently well more to The effectively. customers grew to serve provide our continues

First, and enhancing offerings, to to provide a maximize them their distribution more to to network access customer state-of-the-art a partners services best-in-class our with our and ability solutions their enabling personalized for and integrated continue while patients, innovative experience business performance. provide experience seamless

identify value stakeholders. we create Next, leveraging and and our that all are actionable to new for expertise, shared opportunities capabilities insights execute

market to Finally, they enabling where our ensuring specialty supporting access distribution vital pharmaceuticals, and their more complex them. need practices community-based access are providers pharmaceuticals to patients and and services run when while practice management have to efficiently,

progress continues as PharMEDium, expected. For

the decree at third-party of we continue be open while was inspection consent this they the these will As facilities, continue completing an communicated audit our past inspections we PharMEDium audits in of assessment input a strategic business. The finalized, midst into facility. orders commercial milestones future Memphis currently review ongoing into their operations. important plan the is financial reopen comprehensive, initial May, the to an a from the third-party and two PharMEDium for meaningful consent and decree results are work of these Entering and as

group reported Commercialization to Health on Moving & our Services Animal Global business as Other.

by extremely year-over-year strong double-digit this are Health. income from Group performance operating We with achieved Animal pleased the as MWI quarter their performance led growth,

efficiently customers creating its their quarter, businesses customers expand also their service plans the from executing ways continued MWI solid to improvements. and upon benefited within robust to additional proposition, and pharmaceutical-centered segment. health third base, of from AmerisourceBergen strong the on portfolio The partners. demand patients comprehensive are value technology Services entire to its and the particularly by our animal our through for driving find cost During value and Courier companion World continuing business with and efficiency along customer Consulting new additional MWI

digital technology tools are and patient platforms, additional creating data advancing leading from and Our customer efficiencies, partnerships outcomes manufacturers. new experience enhancing and the

the differentiated needs for for continue solutions health will AmerisourceBergen support the above, companion central enhanced making production access respond further with to that in and industry. pharmaceutical products, AmerisourceBergen manufacturers pharmaceutical As global the animal partner commercialization

community AmerisourceBergen their for cornerstone independent the care providers, devote customers. local and reflects our creating continued pharmacists, commitment unwavering the they recognition value communities. and communities. to their local support support providers downstream patients of and same AmerisourceBergen's relentless toward bring in value access are focus and of our ongoing Community to the that including

record actively support provided week, our conference local independent Neighbor Annual Show practical especially becomes with pharmacy XXXX, hosted clinical and pharmacies movement. Trade Conference community our pharmacy number partners helping Good optimize independent of This community Pharmacy. Last and a engaged a resources, them education businesses, as their we At ThoughtSpot by

is store additional AmerisourceBergen and their mind. resilient to hometown X,XXX themselves and experience their tools from pharmacists to independent their customers As help our customer in pharmacies service-oriented hyper-local resources tell pride entrepreneurs, serve provide. and with independent patients we customizing community and by empowering committed with stories being differentiate that

effectively Pharmacy's our -- a and unique on with tailored market providers services Neighbor to example, focus to networks marketing in-store for the enabling pharmacists their experience business patients, experience and For services community. Good are connect create

performance. provides pharmacies provide tools and operational care they enhance digital effectiveness of the maximize to intuitive help improve to Elevate our and with help more benchmarking introduced pharmacies care. and also their analytics patient personalize impact Provider system the have solutions profitability, Moreover, We measure pharmacists Network

providers of pharmacists and On their broader a to a driver stories and to support industry much and by as independent provider AmerisourceBergen patients, lawmakers. scale, telling advocate customers all our community-based continues solutions

provider problems wavered. and has US AmerisourceBergen a healthcare passion responds or customer to in commitment Our when needs system not the solution being arise.

look creative as add healthcare forward safe support drive pursuit part We opportunities to thinking customers of that chain. always supply transparency and our the and be and as within secure well partners, in value access are a relentless and efficiency, that a a of we'll and solution organization our can for enhance

We AmerisourceBergen the industry supply communities. opioid chain understand a opioid challenges -- take leader of we respond appreciate the solutions as also when local the very seriously. role the entire the challenge our in and and confront like global industry epidemic and healthcare enormity

continue suspicious to do halt access and have a We qualified interfere we orders and other collaborate patients including substances all stakeholders a responsible That and not we our medications. with decisions of with controlled to chain stop patient Notably to and in provider information to to personal providing their to recognized distributor, a shipped our as we clinical diversion. are not be company, opioid-based role we every DEA the partners logistics and very the supply said, made customers, day between work to daily hard the important play physicians. and reports to

Company's of medications. including to commitment have with AmerisourceBergen Company's the the on next oversight opioid will to the releasing we comprehensive be Board's as report responded a month, describing prescription epidemic Building risks transparency, a Company as role how associated opioid distributor a

the are in healthier solving actions every AmerisourceBergen's XX by work reflection united Our driven our create who deliver of responsibility tirelessly XX,XXX problem culture being day of purpose on our associates, innovative to over countries futures. to across

Officer, under priority. and Human the for to people advancing continue a people on Resources Silvana our make defined Our leadership Battaglia, our AmerisourceBergen, advantage top anchoring our the of we purpose and competitive strongly are Chief culture

to making are engage, investments talents. and develop attract we further First,

support corporate one development and and growth our growth career collaboration ABC. our across for Company opportunities the expanding strategy are accelerate We to as

to of Strategy topic strategy along nearly Leslie, identify ago weeks AmerisourceBergen. the all to continue of and in brings talent, create On excited who and partners Chief and and would to directly global attracting strategy me, long-range our manufacturer function. our the value development, welcome in lead and of us our years XX her impeccable Donato, grow for an us pharmaceutical we're that initiatives our joined new implement for industry industry stakeholders. Leslie Officer, drive Leslie's to growth customers healthcare long-term business strategy team provider help expertise and make the with to value a experience few Reporting candidate

supply diversity are Next, keeping our within and inclusion we to our commitments base. workforce and

perfect LGBTQ the equality, As Corporate remain to can on and policies exchange score the can ideas diversity of strengthen diverse that of benchmarking and that and related in corporate are efforts provide Equality enrich workplace on steadfast XXXX to Index, creative a further we tool and we practices nation's of the stakeholders. all to Company, our expanding our premier and the value innovative, solutions inclusion our proud

AmerisourceBergen's culture is another. inspired in collaboration through rooted by through purpose, one mutual shape for respect

also ensuring guiding continue We our and are a safe appreciation strong leading promoting our value need culture, AmerisourceBergen to in work industry collective recognizing enables enabling pharmaceuticals edge. well-positioned growth. Advancing We AmerisourceBergen role value and fortify shareholder access brings to long-term performance creating secure vital sustainable the order and to in them. and while appreciate supports each and be further unique associate people environment and that patients AmerisourceBergen, through and for in our and competitive the for play our to delivering to the principles, recognition

the distribution published distributors Deloitte X,XXX of sharing highly that to pharmaceutical report points two of distribution, research, and this that ecosystem. critical of play system. healthcare and risk industry the manufacturers noted value week, core and XXX,XXX the security products more dollars dispensing. of that inventory and connecting a much US annually pharmacies deliver financial our distributors providers, management, efficiency and information healthcare from manufacturers In The to include unparalleled to the Overall, services do fragmented ship role in XXs which highlighting industries access billions analyzed management in generate markets

in AmerisourceBergen AmerisourceBergen pharmaceutical centric from value continues which utilization takes Alongside is by distribution a and well-established benefit services, the commercialization trends in strategy to and driven industry's in a patient macro and that is US innovation, prescription trends. proposition Care. the growth value proposition, differentiated Health and pharmaceutical unique demographics, advantage market, leader key of possesses

needs partnerships us grow focus manufacturers, and downstream, serve. the segments they solutions, in and address market patients further innovative upstream and on evolve to enables strong providers both and Our customer services of the and each to

than are We responsibility to global and a united leader, steward healthier trusted a our responsible a capital, shareholder's in and more ever, create futures. solutions partner providers, of to manufacturers

fiscal strategy, we head and relationships our long-term execution continue create planning all process, our stakeholders. of business XXXX to we As feel that value position confident to into AmerisourceBergen our for

to turn Jim for discussion the call more our results. of Jim? will I financial over in-depth a quarterly Now

Jim Cleary

prior-year quarter. are Steve. gap] and against Growth Thanks, [Audio the stated. comparisons rates June made

refer our please results, GAAP our to of discussion earnings detailed release. a For

our the diligently proud of As upstream we benefiting of performance down. and work and are fiscal across The both to operating we extremely year, to to efficiency partner the continue our results. of be execution deliver our clearly end strong as of our the associates on choice, is in results businesses we closed

results. discuss morning. main this provide to now will our I quarter areas Turning third two in commentary

adjusted our consolidated detail results our and will I performance. First, quarterly segment

revision Second, cover upward to adjusted XXXX will EPS the fiscal I our guidance.

results. We margin, We revenue growth, an lower quarter third income of count EPS quarter cash operating our and management, had strong growth, income, lower expense. Moving higher operating primarily of diluted $X.XX, the performance with to adjusted now net interest and XX% operating due for to expense flow. increase share EPS a finished

in have $XXX acquisition X%, faster fiscal effectively to expense quarter to related Operating Smith. growth was managing segment Distribution revenue business & primarily management our consolidated synergies XXXX capture move continue and by Commercialization both throughout $XX.X anticipated or on Health Our our million originally solid to revenue profit than the of billion. operating million. been X.X% solid Global We X% Services HD had Pharmaceutical expenses to driven increased we Animal $X.X overall as group. this expenses to billion, increased the focus up and $XX Gross to Services able

up a up had million, $XXX expected impact SG&A points. healthcare better X.X%, Consolidated with related basis line from on margin income X operating than our the we costs. favorable operating was Additionally, benefit

decreased cash to reminder, we year-over-year result as business lapsed to from by interest over balance, As $XX primarily in in a expense lapping an increase the invested Net the four increase previous slightly million interest headwind have comparison. with due million, a rates. average and the headwind of an PharMEDium increase helped an our quarters, income caused that interest our $XX in

continue we fiscal strong year. cash better the interest for income, the expected our year-to-date net Given expect lower than expense our to to be and flow interest

now Moving to taxes. income

tax income Our up was the from year prior quarter. rate XX%, XX.X%

million $XXX diluted Our this We our quarter. decreased count X% XXX shares repurchased share to million shares. of

shares opportunistic a million our year, year. over fiscal of back nine of result of first this As the our $XXX repurchases bought have months we in share

now completes was which billion cash. Regarding turn This excludes balance. Year-to-date, free flow the I'll review of cash $XXX the litigation $XXX had consolidated settlements. billion, results. of adjusted we and cash, free quarter We and million benefit cash held ended $X in of our with of antitrust of was $X.X offshore results, the segment which flow cash the to million US denominated majority our

Beginning continues income revenue margin some to operating $XX.X largest $XXX specialty The of point. billion, increased overall to up strong benefit was X.X%. with its Distribution growth. of from Segment sales, segment about operating and up Pharmaceutical X.X% market Services, our basis million, X growth income product segment with customers

unique customers and industry key positively Our distribution and balanced and our portfolio are drivers performance of specialty leading of differentiate AmerisourceBergen. businesses

that increased while be Distribution success value for impressive teams penetration year both Additionally, our had our to highlight systems worked to notable expenses. our on The businesses will have we existing maintaining focus by customer partners', base. to I continues down, create managing within upstream this our as tirelessly execution our all significant relating operating Pharmaceutical and health

Services operations. includes had animal, Courier, Commercialization & increased ever sales dollar and at In was MWI. MWI it's $X.X an that segment, strength Other revenue wins existing and primarily in exceptionally billion the customer the including to quarter, quarter, growth due and Global Consulting new on AmerisourceBergen to Consulting's billion, X% particularly Canadian Health, growth focus turn to MWI strong now will companion recording customers. driven strong and total World revenue up Animal by which including I first quarter, businesses

relationships optimizing From adding nice businesses. the income this operating XX%. intense expanding segment growth experiencing an quarters is customer This operating customer some delivering up strong quarter, at some to maintaining, from group of particular, and income Other exceptional while its focus $XX with an had million, continues lapping In MWI service and on challenging standpoint, in also operations. benefit multiple

the success Also while fiscal offering compared continue and we the step to of XXXX renewing fiscal completes are in this long-term The in has a taking and segment the service a business. and particularly This the our Lash differentiator to transition results, customer both Fusion in long-term XXXX, XXXX be fiscal to excited continues a platform for continues the be quarter's had Other Lash's about Lash, for and year segment, back relationships of from XXXX. encouraged winning we review be to outlook by results.

to fiscal So XXXX I now turn will guidance. our

at are guidance AmerisourceBergen morning's businesses $X high said new level. we EPS we continue to fiscal this release, to raising As to in range $X.XX press to of guidance our across our from XXXX $X.XX adjusted as execute a $X.XX

have in to range operating the expect our X% range to Distribution our now Pharmaceutical now Turning income. to narrowed We income growth. X% to grow to operating operating we as X% income guidance a of X%

at the Our operating unchanged income high guidance year. segment for single-digit growth for fiscal the Other is

last tax Entering of narrowing rate to approximately to of our year, Regarding XX% are a rate. guidance from guidance XX% range the tax quarter the we of XX%.

flow. Turning now cash to free

range billion, cash significant to $X.X guidance cash $X.X of flow our billion. XXXX we previous free to and Given flow our fiscal expect for year-to-date, adjusted billion be free now between $X.X from billion X.X our up

are lowering XXX previous repurchases amount to million XXX given of we for our million shares, year-to-date, approximately year. share down our the expectation weighted share shares outstanding Regarding expectation approximately from the opportunistic count, shares of for

not for any generic year. we year. expectations full our working pricing making Lastly, both are assumptions around the brand trending pricing relatively line changes and fiscal the to in Broadly with speaking, our for original are pharmaceutical

we Turning performance now expect to fourth strong continue across businesses. AmerisourceBergen's quarter, to the

experienced be contribution lower in to the Notably, reminder, favorability third exit to quarter as in we a the not higher a quarter quarter and operating fourth. the as period the fiscal expecting tends repeat However, tend be our in year are fourth us. we expenses for to the SG&A that

unchanged. As process it corporate remains XXXX, to fiscal pertains our

approach comprehensive the our by current business be year-end allows to fiscal informed planning for our the of the guidance provide fully of end will guidance at We This process. output year. financial

us growing to continues shareholder continue enterprise relationships, closing, In toward to ABC well you value. your long-term have be AmerisourceBergen. and the across one to and strong AmerisourceBergen talent transition the impressive. execution Thank collaboration efficiency to in AmerisourceBergen's positioned across delivered leadership and for customer develop to strategy, in our create interest markets, increase

Q&A. Now to call to I the over our will start operator Operator? the turn

Operator

line first Our question comes from the Guggenheim. Instructions] Glen Santangelo company of from [Operator the of

is sir. Please go line ahead Your open.

Glen Santangelo

wanted each for morning. had and margin in both the fiscal but then us can assess balance Steve of the drove help about Thanks a follow-up. so look talk to the bit, just of And experience Jim better the better and those the 'XX? the a little strong margins question. was really to us the into sense a to for good strength detail, as give Thanks margins in I clearly Thanks. this I those of sustainability some taking year maybe -- the I and quarter, I what segments, wondering trends you if of appreciate unpack we maybe have segments,

Steve Collis

his but like Glen, the to is Cleary literally Jim seat jumping answer. I'd question, answer to off

the going I'm CFO So to opportunity. give our

Jim Cleary

All of about right, details starts good as into it. question, and then and thanks. very feel get general, of in margin Thanks, about up the is, quarter your the Steve. the brought you we in feel Yeah, of Glen, good things performance the we quarter, kind I'll the one

First driving quality financing, offer value safety, of and all, it's we're proposition. so we very security strong and efficiently, feel strong one have like a those services we thing we and and high our feel compensated value logistics, them very very offer we fairly proposition, services margins, our for

look had If strong point basis business services health improvement penetration benefit by basis was physicians, and actually margin income little with up business Distribution, unit, at up margins, really and in up margin. get systems management so we practice the the I'll performance and operating with up operating offer, bit Revenue particular, we here. also. specialty, specialty benefit in and at profit X And performance generic overall all a customers in X.X%, more was details the driven by X.X%, into is good X our Pharma a and and that X.X%, in operating and and had that X.X%, looking wraparound income business, that our operating kind systems Pharma really so X%, gross so in operating we health Distribution X%, of improvement up revenue course a of was very we services strong our expenses point driven

run expense synergies of, Smith I'll rate call management got to, HD than also, and out also then a anticipated. of benefited And we us kind sooner

the So Distribution all that in contributed really in Distribution margin across Pharma strong X point caused performance us Pharma improvement X Distribution. basis things Board actually -- and point those Pharma improvement margin a in basis also there's gross in operating also across and

between Services operating Animal performance had really in kind at margin, gross look in margin Commercialization good business, relevant Health, the margin different operating metric a income, on to and & strong business business very operating other is And mix improvement impact really can and Global very because in our we and units revenue of really segment. that and

strong very health very quarter. in the Health. revenue, Animal about talked the in animal operating in & So good We Global Services margin Commercialization performance

remarks. which had called Courier, solid performance been our in level operating performance time the during We very prepared we has in also for very quite and World and business business at Canadian good a out our Consulting high some

Other margin their So the I'd taking positioned improvement say in are respective advantage of well opportunities markets operating of segment. which the and drove kind really those in businesses very

repeat about performance of And in health the don't won't particularly, operating QX, operating We benefit asked see, expect costs, of don't and expense probably internal built you benefits, QX. same kind asked so guidance interest won't also margins G&A operating very that expect XXXX. to probably increase you the the benefit but business. in of, QX that we about have of performance impact is QX, have to the solid course we We in doesn't our we of our see expecting to our the solid performance, into that some regard you'll very kind QX. With and in are had good

that year-end is we in process We guidance provide are process planning will we quite our results. midst XXXX when the well announce and and of going our XXXX for

Glen Santangelo

the that that supply ask Thank that any business. Are detail. much is, relates are these clearly can specialty question Steve, specialty impact for for proposals of seems you're of up in you just One I'll the sort all these us a you you drugs. regulatory particular, and to the to? on seem the one sort How there driver it coming Thanks given and proposals the follow-up reconcile out to big maybe others, your there so higher prices any, keeps quick and do be that targeting that be chain? of I'll paying there. stop It to attention of business? as to you

Steve Collis

there. really We continued I'm very you. of specialty businesses. a our performance strong Thank our leading in unique proud have of Yeah. portfolio really market companies

don't practices, own services. but management course, of lot we a really Of any practice create

Our is, data. our of oncology [indiscernible] business course, business

Our and had orthopedics being administered Besse even therapies urology, offsetting more Medical work also really including much outside strong a ophthalmology and business responding with to results there. some oncology, Part do of D in

in these so the of to therapies, drugs new many utilization already it's occurring the additive product innovation existing trends. So much settings, in immuno-oncology just fact,

have So great customers. and of just we a portfolio

have Our often customers this. are aggregate of to

relationships in it's there oncology be a for of our even the we as consolidators some difficult QX, key So some to resignings, strong them but environment self-sustaining. smaller are and we also announced with have practices, retaining

in We've tend Company. our practices for place a and lot it relationships of you enduring visions time. have that the customers. that larger have fresh strong to top for some for a team those have long been So really changes some has long-term a is brought good the around been trendy at time, in know, long with generation have a we had there leader But but

pharma these businesses. I position we distribution couldn't with be confident strong. more way the is specialty Our in prouder in just in areas and very relationships these positioned

proceeding year So terrific even in performance there have well. as a fiscal the but just in been 'XX, years

Glen Santangelo

Okay. Thank you.

Operator

the line Nephron question Thank of from Eric you. our of And Research. next comes Percher

Your line is open.

Eric Percher

the other there. looks different blue I'd I to want view get two But the relative you a own the along diversion report, the can your litigation. And we raised balance on in you activity areas you share how on that given the to of without data. appears the And the surface comment And highway to opioid country. maybe question scratch topic, of you. as ongoing It very ARCOS ask maybe that Thank the the plaintiffs? position? to perspective coming, your your whether that's the is case, then part of question, to handing how to operations maybe and do improve love to that anything you relative you ammunition the need

Steve Collis

distribution Well, for data first CEO. also was that XXXX. I've and the the year us took taking CEO my of year through market took that as the was us, brand shifted lot generics Walgreens my in as all in that first -- market substances. Xth a that point all over And the the both as just and and key finished distribution to a we even key controlled we over we change as with over XXXX,

event them called our and you last So helps camps personal the charity the tell -- support, and summer met night the is needs one for had of for I'll of company foundation an crisis with a children as and provide we you story victims few Eluna a know, that the cases. foundation a We quickly. it of

seriously. as one very as you that chain an our This society. crisis that, know employer one seriously. take leader is that It's take affects very a we we It's one supply

our Eric interest. understand report your lot and with role read a I of you think I

We've the collaboratively in which we've to control the We've our collaborate with reported feel of very absence like the orders. information. We suspicious daily a of XXXX. well clear work we but with, our So [indiscernible] daily very and in on a intervals. quite proud is regular suspicious work not done. is I reporting, discharged as the We program substances basis, and on agencies. our as reported to in DEA, excitedly feel all stop and government-sponsored orders work ardently basis, we all revamped tried we've responsibility

into me responsibly one we data really not know, acted there's it's to our for with you I that appropriate state, ABC a one the feel and behind basis, looked really think distribution tied again, a, So back. extremely really has on get at hand don't interesting. this we've center was

that's think you add I say. would So like what anything? Jim, to I

Jim Cleary

that it think really covers well, Steve. Thanks. I

Eric Percher

of you goal both the help identify clear areas to past? to the other of actions report make Is upcoming the or

Steve Collis

we are Yeah, first pleased you transparency. we know benefit -- like been it's the and so positive

have problems transparency. We with no

Our tremendous had oversight. Board has

be the weeks report Board coming about pharmaceutical have chain, our corporate the a as our own from really in will out programs. risk that integrity compliance supply distributor next strong We few talking the on The our program, leading the supply we chain. in

course, game really say We have, our quality here. of even upped this, improvement on more, I'd applies really continued that

in say example AmerisourceBergen and the know a great to that so service, you privilege is, that I want One bring to we more about be I to on customer. would in don't much customers sound arrogant it's any way, but

do be pricing service treated will treated respect, fairness you our we and give you can. with to be we fairest and with You'll best will the

that monitoring very you're So very ethics better good good what a from manage we much position to we expect of prescriptions and is are. you the than in

I example say. just that's could one So

have particularly we bring you know We what about customers on pharmacy that areas service in very, very et [indiscernible] to service scrupulous risk, been cetera. of

covered topics. So I Eric. think we really this Thanks

Eric Percher

Thank you.

Operator

Thank you. Sachs. of And next our the comes of Goldman Robert question Jones line from

Your line is open.

Robert Jones

the some for out as seem at competitor same-store we've of in reported an prescription seen doesn't quarter. current in Great. growth the inflection last helping really It customers from customers. to growth the drivers like referenced the I questions. in who the you to and largest large your quarter, both that go the the you guess, night back growth just highlighted Thanks retail

really growth the in is where channels, fact So I'm from it growth just Steve, of trying more and what health really better those and systems there it just sustainable? and is sense that to is it driving get if a is from. coming curious Is specialty, the

Steve Collis

saw We US is one our to US pharmaceutical indexed growth and businesses AmerisourceBergen solid in differentiator from business. are the very we

Obviously, of headwinds, doing of This long the guidance a with afford a narrow had independents and for are tougher nothing the evident in have comp looked afford they're time they reimbursement of programs acquisition, made Our are with is networks a forefront that interesting they in retail. to participate. what with can can is are They and think been analytics what challenge have of lot our again, there the and some strong at doing in decision pharmacies not new that. that but customers a we a looked things. have Elevate, to has having I to change a participate

with what's going to programs market well, the And I segment. think largest know of think you position we resources, strong Elevate, their know had better access customer, and and that we of data customers, have the they The the to on. a independent the largest WBA, they growth said our areas with well understand and with have we sort very strong are pharmacies that in reimbursement happy own are like we customer understand they our from course, their sourcing

trend would I of there last be these we going and this years, companies there drugs now proud coming D in specialty drugs the one of going. is growth is and ABC. we R&D of this is a manufacturers debates have our these relative this have thing mean, so the One we several sales great is at new performed industries year. the I and that XX portfolio to is to is last going also part just setting, wonderful a the point just night, I of in for much we point customers see listen biotech I to Clearly, and over in is so so specialty. many, distribution innovation public to the on, Part one to we but drug core American went And saw out wonder And much business, specialty where at it's make manufacturing that when and when are the

So positioned just we innovation. and this we're seeing very think of we are benefit well a

Jim, Health you strong segments? anything specific is on pointed any out? as systems

Jim Cleary

the the customers, systems. practices couple a -- mail us systems, we many, I really and that that veterinary as order, anchor And portfolio were this in think offices, things as and in is customers, in benefited what particular, physician call physician really I Steve, benefits of specialty pharmacies, to really broad practices health while you out portfolio. health is broad saying, areas, we Yeah, think, key independent have many of quarter,

those our from will of businesses to Although -- a benefit time. while of over be different that us time, period should strong can businesses parts time longer

So that broad portfolio strength. a real is having

Steve Collis

course and year-over-year earnings I'd growth with say Yeah, of is well. outstanding the as XX% quarter

performance So well. our growth, of some in higher we higher were margin our as proud really businesses of smaller

Robert Jones

And one follow-up if sneak in Jim. just could then for I

this the referenced SG&A expected than a in few benefit You times line. better healthcare

give on sense you was if Just curious, be would of size any us it? could helpful. the you what exactly That that and

Jim Cleary

about that a and and the had second Yeah, last talked we quarter. actually similar benefit quarter, fiscal

and really And experience, our better and of is anticipated kind is getting at the to couple internal due were of so things, one the than change design expenses the lower benefit second year. claims it's benefit beginning and of a that health a we're

most the couple quarters And recent pennies so of couple quarter. benefited that's was a us last in it the and of

Robert Jones

thank Great, you.

Operator

comes from the you. next question with Thank Rhyee Cowen. Charles line And of our

line Your open. is

Charles Rhyee

Hey, bit about Part briefly is of you thanks I I sort oncology Steve, the quarter your Committee D, here. look last little for on kind thought a about question touched space at Finance difficult I obviously taking bit little talked to guys. the back go wanted Medicare a Senate clients more. it Obviously, think, your know being that Bill, a Yeah. the plan earlier. of you

moving you're proposed, sort -- physicians. to now, sort from of move as the for just it solution a to proposed help Looking sort at Obviously and sort they do bills this think the a fee on fixed think for the that's making with, seem a away your I inflation seeing which Bill a of what more with do stand unworkable. you thoughts Senate cap solve you of of of, you Finance that wanted clients? sort and get and your IPI workable

Steve Collis

of safety know, around a [indiscernible] us weekend. we supply things. It really Yeah, acts, the work you our quality and leader those and chain indeed sort lot of business the our for is trade do of other advocacy customers oncology and see integrity this than

in for course We good environment of our and interest are overall be pricing sustainable going to is areas biosimilars course, our that of us. a brand affect very customers, active

on are big also We access. patient

businesses we we Our Lash life-changing patient get of can. is business access as work access many the products of best-known patients as these probably one to with

very we're think we issue. this informed on So

really we experience get where involved ABC, have We the the our in only but I'd since Lash that in and to humbling really industry say we then, we ever in MMA of process. trade political bought ASP. the this. our were included Group think on XXXX, had associations a be our fees not are And I

at process know is political the dynamic You the pretty moment.

month think might an saw and that rules We very rebate drastically be I suddenly. very changed and last understatement.

setting is for fair course think, Charles, and association customers, and we work -- organizations them work believe best that so stay most strong get I example, involved most with and course most our are can our can in [indiscernible] in feel that try really we with reimbursement we to ultimately like patients with access we immuno-oncology for even that the a and they a setting accessible So oncology to affordable. they for represent actually get that be very we advocate the comfortable

that's very are So we really working where strongly.

it's an add? to Anything important Jim, you want there. question

Jim Cleary

it. that think I No, covers Steve. Great,

Steve Collis

I in lot think a first the said question... Jim

Charles Rhyee

can auditing earlier, let And missed if be I is know, the certainly. you Yeah say to you PharMEDium? just me for process did it expect completed when

Steve Collis

that. Jim's going to take

Jim Cleary

Yeah well. facilities progress -- two progressing and are so and the audits in of open our that's

of needs previously at of as call. financial also are and It's account shareholders facilities that And we'll quarter on future we decisions, course best stated not next and headwind we're early our our we of for our third kind comprehensive, customers operations have the we take but so -- during review speculate two will what's And continuing strategic provide we and I will of to into of it's PharMEDium during and continuing PharMEDium updates also PharMEDium. say was the AmerisourceBergen too stated.

loss. in very it slight we fact, be to a don't tailwind it expect quarter, headwind third again, smaller the And in a operating a In was the fourth quarter.

Charles Rhyee

end But sort an itself, at yet date for process moment? there the of is it's the audit like no just set ongoing

Jim Cleary

Charles, expect will that that completed we have process -- month. we expect we this the

Charles Rhyee

Okay.

Steve Collis

feel it that but it take month, up want things just because good these first you than I expect of inevitably on I longer Yeah, this we the yeah. expect, the do wrap it to month. And

Charles Rhyee

a lot Thanks guys. Great.

Operator

next comes our line question of And from Valiquette you. Barclays. of Thank Steven the

line open. Your is

Steven Valiquette

Thanks. Good morning everybody.

it's So suppliers limited calendar for if a we look at far more the exclusive particularly new decent see XXXX, first-time quite products so generic some that number actually of pretty may of wave been in launches, time. in launches

able you're calendar relative if that tracking discuss much curious how generics contribution from new so expectations just of I'm to So 'XX? to in Thanks. your is far

Steve Collis

-- and an on the talked our pipeline I we is. I know our talked generic was I trade to we think number was contributor our is there customers' the You when market beginning we rules. and will market It us at. think first trend the thing which metric we stable discussions you be looked I affected generic was plan few launches, over can it's expected as this really you has The anything that where I And there's announcement the this what we've many at have big profitability authorized that for and on market, talk about it that CEO, years can't similar by explained for think competitor particular seen the times, changed. and think our dynamic. profitability. really nothing the and a be But the know, new rebate transparency and to had We but we've the important know the is specific of we've was product one if and we looked started remains say last that saw at actually week, a generics in

Operator

Lisa JP the with Thank line And you. our Morgan. from next Gill of question comes

is line open. Your

Lisa Gill

flow, just think acquisitions this morning. the strategic you the couple about quarter, much. back to year. talked given areas years in If just very manufacturing strong services. of a cash not the Thanks Steve, in of for I but ago, potential Good

merger, group? you how us component the question. branded up just of can the brought look to trended you on as potential think think you market the would give for be about Just pricing do And you then could buying any my versus as and and expectations follow-up how your you update both side, the that do curious generic, just what quarter that your around at

Steve Collis

Okay.

So second I'll then the do one. one first take Jim the and

thanks So the Lisa. question, for

active. it's We something of with, active. time time something we a I lot a it's we're are important, we spend spend It's and very think Board management lot of with,

team so of has who Bob, founder at the Xcenda. team, really If Bob acquisitions, many our was head and comes now. of other pharma reporting both the really management sector distribution including my team you look from

the those So in have accelerated portfolio could that the say we that, that company of a Fushion, for services benefit that -- of we're good the we we example. have the or of technologies, new really and different services that if need only was in acceleration the and not effect acquisitions investing of process gaining really we'd is areas leasing acquired the

want don't we to and offerings that have. new be just in think, really we and experienced -- I areas add services we these So are behind we well companies new that

you trying and I markets Lash the high grow have think like and organically. So we Courier very to know and really those businesses businesses World be with And standards. we'd

going we us we example need the do million you've a to are to customers to million to good say, a $XXX a -- or us investment? acquisitions every We business is technology of, internal let's lot approximately have helping making lot that do with, invest been environments of that's better. seen year, do of in So easy with our $XXX understand

the well show independent very for We offerings digital received. were our pharmacies, and trade our for example, had last week

are small for XXs than where shareholders in in areas results sometimes up investing low that are our to these we see more So XX trading EBITDA. to fruitful companies our

financially are we driven as well. So

reasonable We're Our to these acquisitions management Board really us a holds stand timeframe. seeing also stand. holds to and us accretive within be the

made and to Certainly been businesses. company. CFO, roles. we but Jim, knows has she and also of commercialization right partnerships, our a brought very things some JVs M&A, more partner our the with done who in Donato great interesting lot job had her in do is we understands Leslie a she's and market, previous a She Leslie think the customer So to going

ago So company we but Smith to and of our complete also a this be of a as a give HD I portfolio to to market really are right has an is we that's end us almost all accelerant the long that this core on example share. model synergy going it business on has the capture it I new think our and area, think focused at by We price did year. the for in fiscal good be executing

Jim, please question. answer the second

Jim Cleary

on you inflation were are And get sure. second Yes, generic into believe and right. is But, I I'll brand question those. the deflation,

Our lot Lash, fiscal is business share of question year-to-date $XXX repurchases inflation is the ask, expected. done have we our regard a branded services that investing with to over fiscal World of Fusion expected But yes, for we been And and very our strong, like NOVA digits in we've in year had and XX% and this buy also flow as service. guidance, million you manufacturer deflation side as course, as cash of set you inflation, year and margin know, directionally would our and mid-single directionally branded in 'XX fee Courier.

and for that price year that from in generic those in original manufacturers economics. range kind deflation, of in range we beginning the of relies generally expectations. on So also And increases had of our the original kind really the the expectations it's of out put X% generally other of at

Bennett Murphy

we And question. have time more operator, for one

Operator

question Goldwasser And line of Morgan of our comes from the Perfect. Ricky Stanley. last

open. is line Your

Ricky Goldwasser

you. morning. thank Great, Good

Do with So as my any other any And question with is share other about of have clear do introduce the OneOncology. relationships it formularies? a you and -- to you partnership form profits an similar to structured? opportunity is see do strategic providers? you this, How opportunities part

Steve Collis

Yes.

management become -- practice with announced and OneOncology. We some and It's ION a of certainly, partnership again, oncology is a division. we really certainly contracting these And bigger. which have groups

Our relationship with is interesting. them always

practice them adding on keep a of to they us that's of challenge sort have going states. value to various they contracting to expand services, new new into as level think I really

other of three Ricky we aggregation we customers have and that with and in two that practice are that -- the that new, the -- in other is strong are have, or contracting region. We business OneOncology customers are very

practices too seen of get sort sector. two of when of that So three founding practices we've existing this situation two is the this but -- and new you I go to not in is on other of a business think OneOncology granular, were founding And many customers. three were our to

and in we participated, prime provider I So for that that we're the actively customer. be AmerisourceBergen proud to very think vendor the was services chosen

Thank you for the question.

I So on our going Other think with third the I And that, quarter tremendous sector. that execution year Pharma just and Distribution want we're call. business, the up that a to to both our year for say wrap has this been of on

well. is working corporate to of challenges reimbursement arise, situations We're very staff it Our be responding or opioid as that ABC. the process one

I think behind you're seeing issues PharMEDium and us. resolved an intention the get to

and really customers investments expansion, work knows in cash the the it successful well to you successful, nine of has just the point would the as months execution. long-term, and on they have flow, which be ensure team or those is AmerisourceBergen I been is placed made key And them our look just keep are to this that and internal whether acquisitions AmerisourceBergen with program, focus supply drivers how management business really an the and turn I internal really So at strong channel, our that deployment we of successful. just that in capital marketplace to solid think

this such you. So has thank you share. results you been a for good your hour pleasure time with Thank this with today. to having And

Operator

does Teleconference that your today. gentlemen conference using Executive conclude and Service. AT&T and Thank for for you for your Ladies participation

disconnect. now may You

Cencora (COR) 1 Aug 192019 Q3 Earnings call transcript